phenomenon
antibodydepend
enhanc
ade
underli
sever
diseas
across
entir
spectrum
microb
vertebr
inde
ade
could
classifi
fifth
type
immunopatholog
tabl
type
igemedi
immedi
hypersensit
type
ii
iggmedi
acut
immun
complex
diseas
type
iii
iggmedi
foreign
antigencomplementdepend
immun
complex
diseas
type
iv
cellmedi
immun
autoimmun
diseas
type
v
infecti
immun
complex
enhanc
microbi
infect
fcrbear
cell
past
four
decad
differ
line
scientif
inquiri
coalesc
sharpen
understand
antibodymedi
mechan
govern
sever
infect
wide
spectrum
microorgan
independ
studi
host
respons
acut
chronic
human
anim
infecti
diseas
gener
evid
crosslink
immun
complex
receptor
increas
intracellular
infect
contribut
diseas
sever
one
earliest
descript
activ
came
neutral
studi
murray
valley
enceph
viru
mvev
exposur
viru
presenc
dilut
avian
antibodi
result
greater
clearanc
chick
embryo
fibroblast
monolay
virusonli
control
followup
research
suggest
phenomenon
result
stabil
mvev
antibodi
differ
explan
emerg
sequenti
infect
human
dengu
virus
denv
shown
produc
sever
diseas
dengu
hemorrhag
fever
dhf
initi
studi
ade
assum
increas
viru
output
case
approach
result
extrins
phenomena
avid
attach
monocyt
macrophag
increas
intern
infecti
immun
complex
via
interact
receptor
compar
viru
alon
observ
numer
system
howev
effect
igg
opson
complement
complex
phenomenon
involv
suppress
innat
cellular
immun
unexpectedli
incub
ross
river
viru
rrv
dilut
rrv
antiserum
result
enhanc
infect
mous
macrophag
cell
line
primari
human
monocytesmacrophag
via
innat
immun
suppress
involv
reduc
product
reactiv
nitrogen
radic
via
downregul
product
abolish
interferon
regulatori
factor
nuclear
gene
express
remark
mark
increas
gene
transcript
protein
product
observ
surprisingli
ligat
zymosanantibodi
complex
presenc
rrv
exhibit
transcript
pattern
indic
featur
opson
pathogen
involv
drive
immun
suppress
similarli
mani
investig
show
igg
bound
surfac
leishmania
amastigot
intracellular
mammalian
hostdwel
parasit
stage
induc
cytokin
turn
suppress
protect
immun
respons
parasit
downregul
induc
synthas
ino
inhibit
cell
develop
product
henc
igg
respons
usual
protect
usurp
parasit
surviv
tcell
immun
fail
presenc
abund
igg
antiamastigot
antibodi
infect
start
lethal
cours
thu
ade
complex
phenomenon
antibodymedi
interact
fc
receptor
may
involv
alter
pathogen
uptak
macrophag
monocyt
also
cellular
respons
intern
pathogen
antibodyenhanc
viral
infect
requir
initi
adapt
immunolog
event
term
sensit
occur
three
set
primari
infect
natur
occur
heterotyp
virus
genera
infect
virus
creat
antigen
divers
rapid
evolut
biolog
antigen
variant
cours
chronic
infect
immun
result
incomplet
protect
immun
tabl
review
halstead
tirado
yoon
ade
phenomenon
attract
wide
interest
virolog
mani
virus
replic
macrophag
vivo
manifest
antibodyenhanc
infect
diseas
dengu
virus
denv
group
four
close
relat
member
flaviviru
genu
denv
share
genet
homolog
inocul
bite
infect
aed
aegypti
mosquito
initi
infect
four
denv
rais
protect
typespecif
antibodi
addit
crossreact
nonneutr
antibodi
may
enhanc
infect
differ
denv
type
inde
infectionenhanc
antibodi
risk
factor
enhanc
dengu
diseas
infant
regularli
acquir
sever
dengu
diseas
first
dengu
infect
matern
polyclon
dengu
antibodi
circul
protect
level
uniqu
illustr
ade
phenomenon
human
medicin
human
secondari
dengu
infect
follow
stereotyp
cours
sever
outcom
includ
shock
gastrointestin
hemorrhag
accompani
vascular
collaps
result
capillari
permeabl
occur
around
time
defervesc
high
level
viremia
earli
diseas
high
level
vitro
studi
indic
major
requir
ade
activ
subneutr
antibodi
concentr
practic
antibodi
direct
surfac
epitop
involv
viru
entri
effici
produc
ade
studi
ade
cell
model
human
monocyt
receptorbear
continu
cell
line
intracellular
denv
product
increas
result
idiosyncrat
receptor
signal
immun
complex
ligat
least
two
type
suppress
pathway
express
figur
collect
pathway
downregul
antivir
respons
adeinfect
target
cell
result
adeinfect
cell
secret
reduc
level
typei
ifn
time
suppress
transcript
translat
facilit
express
synthesi
antiinflammatori
cytokin
ade
infect
also
suppress
innat
antidenv
mediat
nitric
oxid
radic
disrupt
transcript
ino
gene
transcript
factor
believ
mediat
conclud
vitro
ade
infect
facilit
viral
entri
also
modifi
innat
adapt
intracellular
antivir
mechan
result
enhanc
denv
replic
critic
respons
observ
vivo
genomewid
transcriptom
peripher
blood
mononuclear
cell
pbmc
collect
acut
phase
children
dengu
fever
df
dengu
hemorrhag
fever
dhf
indic
patient
dhf
decreas
level
reduc
ifn
transcript
increas
blood
level
compar
patient
milder
ill
studi
acut
stage
sever
diseas
increas
product
downregul
multipl
ifn
regulatori
gene
note
protect
role
ifn
moder
dengu
infect
demonstr
mous
model
suggest
human
df
precis
role
immun
complexelicit
product
clinic
evolut
sever
dengu
infect
well
understood
may
respons
observ
shift
observ
dhf
result
obtain
studi
ade
continu
human
fcrbear
cell
subject
critic
caveat
respons
observ
faith
occur
vivo
dengu
ade
studi
four
differ
primari
human
myeloid
cell
deriv
peripher
blood
leukocyt
pbl
donor
viral
infect
cytokin
respons
differ
significantli
human
monocyt
activ
macrophag
matur
dendrit
cell
dc
support
ade
immatur
dc
infect
macrophag
denv
alon
fulli
neutral
immun
complex
stimul
high
level
ifn
downmodul
ade
condit
replac
secret
type
ifn
neither
produc
suppress
ade
infect
monocyt
denv
howev
ade
infect
primari
monocyt
synthesi
peak
serum
dilut
produc
peak
viru
yield
precis
mechan
fuel
enhanc
product
dengu
viru
monocyt
macrophag
requir
studi
neither
product
suppress
type
interferon
critic
ade
phenomenon
evid
degre
antibodi
opson
may
impact
interact
result
differenti
process
surfacebound
viru
particular
model
larg
immun
complex
found
stimul
result
inhibit
cellular
uptak
consid
contribut
fcrmediat
phenomena
cours
acut
infecti
diseas
import
note
differ
kinet
microbi
invas
respons
infect
infect
vertebr
divid
affer
effer
event
affer
event
relat
invas
propag
surviv
infect
organ
effer
event
contribut
reduc
retard
elimin
infect
organ
infect
produc
diseas
affer
event
success
predomin
earli
stage
effer
event
may
culmin
elimin
invad
organ
cure
ade
phenomenon
igg
antibodi
residu
previou
dengu
infect
whether
activ
produc
passiv
acquir
act
power
affer
event
igm
case
secondari
dengu
infect
igg
dengu
antibodi
play
import
role
effer
event
dengu
infect
includ
clear
extracellular
viru
activ
complement
mediat
adcc
dengueendem
countri
second
heterotyp
dengu
infect
respons
dhf
primari
dengu
infect
infant
account
remaind
vitro
ade
literatur
make
clear
antibodi
virtual
flaviviru
enhanc
dengu
viru
infect
fcrbear
cell
southeast
asia
dengu
virus
cocircul
japanes
enceph
je
india
je
west
nile
pakistan
west
nile
australia
kunjin
strain
west
nile
american
region
yellow
fever
use
yellow
fever
vaccin
direct
examin
enhanc
denv
infect
human
monocyt
cell
line
antibodi
rais
human
experienc
appar
wildtyp
je
infect
neg
howev
studi
screen
ade
singl
high
dilut
serum
report
enhanc
dengu
infect
prior
west
nile
yellow
fever
infect
vaccin
howev
recent
observ
children
thailand
either
wildtyp
je
infect
immun
kill
je
vaccin
experienc
mild
overt
dengu
diseas
higher
frequenc
dengu
viru
infect
suscept
individu
dengu
infect
jeimmun
increas
frequenc
mild
overt
dengu
diseas
ensu
ill
last
two
time
longer
dengu
ill
suscept
prior
observ
thought
je
vaccin
actual
reduc
sever
dhf
accompani
second
dengu
infect
second
denv
infect
occur
combin
least
document
result
hospit
diseas
human
experiment
establish
denv
infect
refractori
period
three
month
follow
initi
denv
infect
present
briefli
shortli
primari
denv
infect
abund
heterotyp
antibodi
may
form
larg
immun
aggreg
neutral
solut
elimin
standard
phagocyt
clearanc
macrophag
refractori
period
second
dengu
infect
occur
express
clinic
ill
vari
amount
heterotyp
neutral
antibodi
rais
follow
primari
dengu
infect
natur
histori
antibodi
respons
follow
infect
denv
includ
heterotyp
antibodi
essenti
unknown
heterotyp
antibodi
critic
import
modul
second
denv
infect
low
dilut
preinfect
sera
children
unappar
secondari
denv
infect
almost
invari
reduc
neutral
denv
primari
human
monocyt
preinfect
sera
children
develop
ill
requir
hospit
detect
heterotyp
neutral
antibodi
observ
suggest
low
level
heterotyp
neutral
antibodi
antidenv
prevent
downregul
denv
clinic
respons
around
onefifth
monotyp
dengueimmun
schoolchildren
lack
heterotyp
denv
antibodi
develop
dhf
infect
denv
virtual
ratio
occurr
dengu
shock
syndrom
dss
sequenti
denv
denv
rayong
thailand
sequenc
infect
may
highli
determin
diseas
sever
secondari
denv
infect
pathogen
cohort
studi
rayong
thailand
specif
infect
sequenc
associ
dss
case
known
viru
isol
acutephas
sera
antibodi
preill
sera
appli
origin
antigen
sin
phenomenon
pair
sera
although
secondari
denv
infect
common
year
dss
occur
secondari
denv
infect
burmes
worker
came
similar
conclus
longitudin
seroepidemiolog
studi
yangon
myanmar
contrast
indonesian
studi
dss
associ
sequenc
end
denv
denv
even
though
secondari
denv
infect
common
yearold
children
immun
denv
time
pathogen
establish
denv
infect
sequenc
may
chang
notabl
rapid
increas
pathogen
express
secondari
denv
infect
denv
month
month
cuba
complet
partial
sequenc
denv
virus
isol
begin
end
outbreak
identifi
structur
genet
mutat
consist
amino
acid
chang
posit
protein
complex
studi
managua
nicaragua
attribut
yeartoyear
increas
diseas
pathogen
express
combin
genet
chang
denv
wane
denv
immun
affect
children
essenti
none
field
observ
subject
studi
use
cultur
primari
human
myeloid
cell
work
cite
must
conclud
ade
studi
perform
continu
human
myeloid
cell
instead
character
primari
human
myeloid
cell
date
research
carri
use
denv
studi
ade
extend
quickli
possibl
complet
rang
dengu
virus
use
typespecif
polyclon
human
antibodi
rather
mous
even
human
monoclon
antibodi
observ
human
dengu
ill
need
better
understand
ade
phenomenon
context
understand
dhf
infant
accompani
primari
denv
infect
acquir
latter
half
first
year
life
import
attract
recent
research
interest
uniqu
clinic
phenomenon
illustr
role
play
dengu
antibodi
modul
diseas
express
also
bifurc
roleprotect
sever
month
birth
high
concentr
enhanc
infect
month
later
subneutr
concentr
contribut
immatur
denv
particl
ade
interest
immatur
den
virion
infecti
human
myeloid
cell
presenc
enhanc
dengu
antibodi
ade
infect
occur
readili
surmis
immatur
denv
releas
circul
human
infect
antibodi
prm
immatur
denv
antigen
frequent
observ
note
made
possibl
role
differ
receptor
mediat
ade
macrophag
leishmania
mous
model
interest
observ
suggest
ligat
may
affect
fate
larg
immun
complex
immun
clearanc
phase
dengu
infect
real
research
challeng
document
critic
receptor
oper
human
veterinari
clinic
microbi
diseas
enhanc
episod
import
studi
specif
outcom
ade
infect
differ
wildtyp
dengu
virusesantibodi
combin
includ
appropri
genotyp
variant
possibl
differ
combin
denv
dengu
antibodi
matter
antibodi
flavivirus
uniqu
differ
effect
monocyt
macrophag
innat
immun
requir
care
studi
wide
held
process
elimin
dengu
virusinfect
cell
gener
cascad
chemokin
cytokin
contribut
pathophysiolog
dengu
diseas
syndrom
term
perfect
cytokin
storm
given
evid
increas
infect
cell
mass
sever
dengu
infect
cytokin
gener
viru
infect
interact
virusinfect
cell
host
immun
respons
would
appear
quantit
proport
viral
load
exagger
abnorm
dengu
cytophil
viru
cellular
infect
proce
infect
cell
elimin
wide
misconcept
peak
viremia
occur
earli
infect
repres
peak
viral
load
fact
quantiti
viru
blood
cours
infect
describ
kinet
extracellular
viru
clearanc
use
sensit
techniqu
intrathorac
inocul
toxorrhynchit
splenden
mosquito
observ
dengu
viru
could
detect
nearli
plasma
sampl
collect
within
hour
onset
fever
frequenc
viru
isol
declin
rapidli
viru
usual
present
defervesc
viremia
longer
durat
individu
experienc
primari
dengu
viru
infect
experienc
secondari
dengu
viru
infect
slope
declin
viru
titer
greater
individu
dhf
df
import
mechan
extracellular
viru
clearanc
thought
igm
igg
dengu
antibodi
although
lymphocyt
antibodydepend
cell
kill
may
contribut
attack
destroy
virusinfect
cell
discuss
like
elimin
dengu
virusinfect
cell
continu
well
onset
antibodi
product
result
peak
cellular
infect
viral
load
around
time
defervesc
cellular
infect
elimin
well
end
viremia
interest
major
effort
fail
detect
circul
cell
late
acuteil
phase
dhf
patient
suggest
author
cell
might
locat
tissu
dengu
viru
replic
occur
altern
japanes
enceph
model
antibodi
compon
adapt
immun
respons
may
play
much
import
role
termin
dengu
infect
heretofor
thought
involv
ade
tabl
felin
coronavirus
circul
two
form
felin
enter
coronaviru
fecv
pathogen
minor
signific
howev
spontan
mutat
viru
yield
fipv
capabl
replic
periton
macrophag
produc
periton
occasion
fip
fatal
arthuslik
pyogranulomat
diseas
kitten
cat
ade
incrimin
diseaseenhanc
factor
antibodi
pathogen
evidenc
observ
kitten
acquir
passiv
matern
fipv
antibodi
develop
rapid
fulmin
diseas
follow
challeng
fipv
seroneg
diseas
enhanc
demonstr
cat
infect
presenc
vaccinederiv
humor
immun
direct
spike
protein
fipv
tabl
similarli
cat
immun
recombin
vaccinia
viru
ref
express
spike
protein
fipv
die
earlier
control
anim
adult
cat
fipv
develop
chronic
infect
felin
coronavirus
fecv
mutat
fipv
gain
macrophag
tropism
antibodi
respons
mount
fipv
infect
diseas
sever
enhanc
summari
antibodi
respons
fipv
occur
cours
infect
passiv
transfer
antibodi
natur
infect
immun
kill
recombin
vaccin
led
enhanc
fipv
diseas
enhanc
diseas
sever
attribut
larg
presenc
nonneutr
antibodi
leishmaniasi
caus
protozoan
parasit
genu
leishmania
transmit
bite
certain
speci
sandfli
human
infect
caus
leishmania
speci
infect
mammal
diseas
exist
two
major
form
cutan
viscer
leishmaniasi
viscer
leishmaniasi
vl
sever
form
leishmaniasi
second
largest
parasit
killer
world
malaria
respons
estim
case
year
worldwid
leishmania
transmit
sandfli
promastigot
motil
form
parasit
macrophag
spread
within
host
amastigot
oblig
parasit
macrophag
human
host
respons
infect
leishmania
vari
speci
patient
immun
reaction
patient
whose
lymphocyt
produc
amount
cell
often
recov
cutan
infect
recoveri
immun
reinfect
patient
infect
viscer
form
parasit
make
high
level
antiparasit
antibodi
contribut
host
defens
without
treatment
patient
like
succumb
vl
mous
model
exist
studi
cutan
vl
exampl
normal
balbc
mice
suscept
diseas
develop
progress
nonheal
lesion
numer
intracellular
parasit
within
macrophag
despit
presenc
high
level
antiparasit
antibodi
mimick
human
vl
parasit
often
dissemin
liver
spleen
bone
marrow
vitro
model
also
availablepromastigot
amastigot
infect
cultur
bone
marrow
periton
macrophag
mice
differenti
peripher
blood
human
monocyt
number
mammalian
cytokin
discov
among
mous
cytokin
synthesi
inhibitori
factor
produc
cell
later
renam
type
ii
cytokin
found
member
famili
cytokin
includ
cytokin
similar
intronexon
genom
organ
bind
receptor
similar
structur
case
share
compon
activ
janu
kinas
jak
signal
transduc
activ
transcript
stat
signal
pathway
capabl
inhibit
synthesi
proinflammatori
cytokin
gmcsf
also
display
potent
abil
suppress
antigen
present
capac
antigenpres
cell
howev
set
immunosuppress
enhanc
nk
bcell
surviv
bcell
antibodi
product
made
macrophag
varieti
cell
includ
reg
play
import
role
regul
immun
respons
also
increas
host
suscept
intracellular
infect
mous
model
cutan
leishmaniasi
suscept
leishmania
major
associ
respons
cell
suscept
balbc
mice
produc
infect
l
major
cell
resist
mice
express
transient
deplet
cell
vivo
neutral
balbc
mice
promot
kill
intracellular
parasit
heal
leishmani
lesion
determin
suscept
howev
suscept
balbc
mice
lack
fulli
resist
infect
furthermor
human
dichotomi
pronounc
appear
major
induc
suscept
human
viscer
leishmaniasi
vl
level
plasma
directli
correl
diseas
sever
identifi
lymph
node
taken
patient
vl
pbmc
acut
viscer
leishmaniasi
respond
stimul
leishmania
lysat
produc
mrna
ad
pbmc
suppress
product
treatment
pbmc
patient
acut
vl
demonstr
mark
increas
prolif
respons
leishmania
lysat
vitro
studi
leishmaniainfect
periton
bone
marrow
macrophag
demonstr
intracellular
kill
organ
classic
activ
macrophag
could
inhibit
administr
exogen
endogen
macrophag
product
greater
clariti
achiev
reciproc
action
recogn
complementari
cytokin
act
directli
cell
enhanc
prime
product
revers
prime
potent
cytokin
induct
leishmanicid
activ
macrophag
sustain
product
respons
infect
commonli
associ
develop
specif
tcell
respons
administr
increas
product
reduc
sever
leishmania
major
infect
mice
potenti
vaccinederiv
immun
depress
product
howev
exposur
macrophag
suscept
mice
opson
leishmania
promastigot
suppress
express
import
macrophag
receptor
gener
cytokin
leishmaniainfect
macrophag
recogn
product
balbc
mous
bone
marrow
macrophag
respons
lp
suppress
ligat
fcr
complement
scaveng
receptor
mrna
synthesi
protein
secret
diminish
nearundetect
level
follow
receptor
ligat
suppress
specif
sinc
product
inhibit
also
ligat
mous
immun
complex
shown
enhanc
product
stimul
mous
bone
marrow
macrophag
lp
result
product
addit
rbc
opson
igg
antibodi
dramat
enhanc
product
immun
complex
induc
activ
macrophag
produc
also
induc
macrophag
dendrit
cell
switch
product
modul
macrophag
result
differ
mechan
wherea
abrog
biosynthesi
properti
share
ligat
sever
macrophag
receptor
induct
specif
addit
evid
role
support
chronic
infect
obtain
normal
balbc
mice
develop
progress
nonheal
lesion
numer
leishmania
major
parasit
balbc
mice
control
diseas
progress
rel
small
lesion
fewer
parasit
fifth
week
infect
furthermor
establish
l
donovani
viscer
infect
normal
mice
receptor
monoclon
antibodi
mab
treatment
success
induc
intracellular
parasit
kill
within
liver
macrophag
studi
show
amastigot
leishmania
exploit
unusu
unexpect
virul
factor
host
igg
surfac
leishmania
amastigot
coat
igg
result
immun
complex
allow
ligat
receptor
inflammatori
macrophag
preferenti
induc
product
high
amount
induct
iggamastigot
occur
macrophag
mice
lack
common
gamma
chain
signal
indic
one
three
receptor
involv
subsequ
studi
use
defin
immun
complex
demonstr
three
signal
gamma
capabl
signal
product
macrophag
implic
studi
set
igg
bias
immun
respons
toward
respons
inde
speci
leishmania
chronic
infect
requir
amastigot
coat
igg
phenomenon
well
establish
induct
ligat
gener
process
demonstr
nonmicrobi
antigen
lipopolysaccharidetr
balbc
mous
macrophag
expos
ovalbumin
ova
alon
develop
tcell
respons
driven
character
product
antigen
complex
igg
antiova
tcell
respons
driven
produc
phenotyp
stabl
retain
cell
subsequ
restimul
nonbias
condit
mice
vaccin
iggopson
ova
made
high
level
igg
ab
igg
isotyp
tcell
bias
revers
via
ligat
also
observ
vivo
use
macrophag
gene
knockout
mice
product
cell
shown
control
macrophag
cytokin
respect
studi
demonstr
ligat
activ
macrophag
revers
bias
accompani
innat
immun
respons
microbi
product
importantli
patient
vl
high
level
antileishmani
antibodi
correl
peak
parasitemia
neg
dth
respons
success
treatment
leishmaniasi
amphotericin
result
decreas
antibodi
titer
restor
dth
respons
earlier
observ
identifi
polyclon
bcell
activ
high
level
immun
complex
well
rheumatoid
factor
patient
vl
human
infect
leishmania
donovani
higher
frequenc
rheumatoid
arthriti
experiment
model
vl
infect
hamster
develop
immun
complex
glomerulonephr
observ
wide
confirm
mous
model
addit
leishmania
donovoni
l
major
humor
immun
respons
l
mexicana
effect
kill
organ
hide
parasitophor
vacuol
host
iggcoat
amastigot
gener
immunosuppress
respons
infect
macrophag
similar
observ
although
perhap
occur
differ
mechan
may
involv
l
amazonensisinfect
jhd
mice
infect
minim
absenc
b
cell
antibodi
immun
element
restor
leishmania
lesion
progress
process
thought
involv
cell
antibodyco
amastigot
result
product
macrophag
ligat
macrophag
produc
rapid
enhanc
activ
two
mapk
erk
activ
erk
lead
phosphoryl
serin
histon
gene
make
promot
access
transcript
factor
gener
respons
activ
activ
mapk
requir
synthesi
addit
erk
activ
inflammatori
stimulu
lowmolecularweight
hyaluron
acid
extracellular
matrix
must
also
present
combin
two
signal
result
superinduct
macrophag
lack
macrophag
treat
inhibitor
spleen
tyrosin
kinas
activ
follow
ligat
fail
activ
erk
consequ
fail
produc
follow
infect
leishmania
amastigot
recent
howev
observ
igg
igg
induc
mous
macrophag
vitro
equal
well
differ
subtyp
igg
igg
primarili
also
sharp
contrast
mice
lack
igg
develop
earlier
stronger
igg
igg
igm
respons
leishmania
mexicana
infect
yet
resist
infect
thu
igg
igg
igg
pathogen
vivo
agreement
prior
studi
indic
requir
chronic
diseas
call
question
assumpt
mous
macrophag
secret
respons
igg
igg
immun
complex
import
sourc
gener
engag
l
mexicana
infect
possibl
fcrmediat
enhanc
diseas
occur
across
broad
rang
microorgan
receiv
littl
attent
research
commun
possibl
ade
contribut
sever
chronic
diseas
exist
larg
number
bacteria
replic
partial
sole
human
macrophag
larger
microorgan
infect
macrophag
profession
intracellular
pathogen
often
produc
chronic
infect
inde
one
criteria
success
parasit
microorgan
produc
system
infect
may
abil
evad
macrophag
microbicid
mechan
defens
mechan
subject
intens
scrutini
chronic
infect
antigen
related
microorgan
may
contribut
format
pathogen
igg
immun
complex
control
microbi
surviv
infect
may
analog
leishmania
model
includ
mycobacterium
tuberculosi
mtb
mycobacterium
lepra
legionella
pneumophila
listeria
monocytogen
brucella
spp
salmonella
spp
shigella
spp
coxiella
burnetii
anaplasma
phagocytophilum
ehrlichia
chaffeensi
well
anoth
protozoan
toxoplasma
gondii
fungi
eg
histoplasma
capsulatum
role
fc
receptor
immun
complex
mediat
immunopatholog
studi
exhaust
organ
list
howev
interest
find
made
tuberculosi
although
studi
resist
tuberculosi
center
tcell
immun
recent
experi
mice
defici
inhibitori
show
improv
bacteri
control
diminish
patholog
day
follow
aerosol
challeng
mycobacterium
tuberculosi
enhanc
product
observ
mice
share
common
subunit
promot
polar
naiv
cell
effector
treatment
human
macrophag
exogen
combin
blockad
reduc
burden
mycobacteri
infect
infect
character
enhanc
protect
respons
coincid
heighten
activ
macrophag
human
elev
level
correl
suppress
host
defens
exacerb
infect
model
reactiv
tuberculosi
presenc
macrophagederiv
lung
infect
transgen
mice
permit
cell
effici
express
effector
function
secret
suffici
induc
classic
macrophag
activ
character
express
howev
mycobacteria
surviv
success
prolifer
within
mous
macrophag
product
control
human
promot
macrophagederiv
appear
overrid
classic
macrophag
activ
effector
mechan
mtb
induc
altern
activ
phenotyp
date
explicit
contribut
mtbigg
antibodi
complex
toward
modul
infect
model
system
report
success
pathogen
arm
array
weapon
includ
penetr
cell
attach
factor
galaxi
defens
innat
immun
respons
much
known
still
much
learn
offens
attribut
microbi
pathogen
howev
ade
phenomena
antibodi
like
complement
contribut
gener
thu
far
poorli
explor
affer
diseas
mechan
mani
infecti
diseas
addit
exampl
cite
cogniz
need
balanc
protect
potenti
harm
antibodi
activ
remain
import
concern
vaccin
develop
